Cannabidiol Oil

ApprovedSmall molecule

WWest Virginia University

Cannabidiol Oil is one of 152 small molecule programs targeting Cognitive impairment. It is currently in Approved.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Nausea and VomitingActive, not recruiting

Intellectual DisabilityActive, not recruiting

Anxiety DisorderActive, not recruiting

DementiaActive, not recruiting

Cognitive ImpairmentApproved

Active, not recruiting

Nausea and VomitingPhase 1

Active, not recruiting

Intellectual DisabilityPhase 2

Active, not recruiting

Anxiety DisorderPhase 3

Active, not recruiting

DementiaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Cannabidiol Oil

WWest Virginia University

Approved

1 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Provigil

NNuvo Research GmbH

Phase 3

1 6

Xarelto

WWim Janssens

Phase 3

1 7

Viagra

VViatris Specialty LLC

Phase 3

1 8

Donepezil Hydrochloride

Eisai

Phase 3

3 9

Statins

Sanofi

Phase 3

1 10

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Alcohol Use Disorder

NCT05159830

Q2 2029

Phase 1Recruiting

Driving

NCT06686914

Clinical

Trials by Indication[1]

Driving2 trials

The Effects of Cannabidiol on the Driving Ability of Healthy Adults

Completed·WWest Virginia University·Phase 2·NCT04590495·40 enrolled

The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex

Recruiting·WWest Virginia University·Phase 1·NCT06686914·300 enrolled

Nausea and vomiting1 trial

Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting

Unknown status·TThe University of The West Indies·Phase 1·NCT06137027·120 enrolled

Cognitive impairment1 trial

The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

Unknown status·—·Phase 4·NCT05022186·90 enrolled

Interaction1 trial

Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction

Completed·OOregon Health and Science University·Phase 4·NCT04396730·9 enrolled

CBD1 trial

CBD Knee Scope Study

Unknown status·FFoundation for Orthopaedic Research and Education·Phase 1·NCT05934500·100 enrolled

7 more indications

Recovery1 trial

Topical Cannabidiol Cream and Post-exercise Recovery

Withdrawn·UUniversity of New Mexico·Phase 1·NCT05044936

Dementia1 trial

Cannabidiol's Role in Dementia Management

Not yet recruiting·—·Phase 2/3·NCT06514066·486 enrolled

Postoperative Pain Control1 trial

Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery

Completed·FFoundation for Orthopaedic Research and Education·Phase 1·NCT05240755·40 enrolled

Alcohol Use Disorder1 trial

Cannabidiol for Reducing Drinking in Alcohol Use Disorder

Recruiting·HHôpital le Vinatier·Phase 2·NCT05159830·76 enrolled

Anxiety Disorder1 trial

Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Unknown status·MMcMaster University·Phase 3·NCT03549819·50 enrolled

Effectiveness1 trial

Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.

Unknown status·PPomeranian Medical University Szczecin·Phase 2·NCT04609748·30 enrolled

Intellectual disability1 trial

Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability

Completed·MMurdoch Childrens Research Institute·Phase 2·NCT04821856·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Cannabidiol Oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cannabidiol Oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cannabidiol Oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West Virginia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWest Virginia University

Cannabidiol Oil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Trials by Indication[1]

Driving2 trials

Nausea and vomiting1 trial

Cognitive impairment1 trial

Interaction1 trial

CBD1 trial

Recovery1 trial

Dementia1 trial

Postoperative Pain Control1 trial

Alcohol Use Disorder1 trial

Anxiety Disorder1 trial

Effectiveness1 trial

Intellectual disability1 trial

References

Drug Info

Quick Facts

Related News